Read the latest from M8.
Feb 28, 2023
M8 Pharmaceuticals and Daewoong Pharmaceutical strengthen their strategic partnership by signing an exclusive licensing agreement for Envlo™ (Enavogliflozin) for Brazil and Mexico
Oct 03, 2022
moksha8 officially rebrands as M8 Pharmaceuticals
May 05, 2022
M8 Pharmaceuticals Announces approval of Mokbio® PS128™ in Mexico
Oct 05, 2021
M8 Pharmaceuticals Announces License of Exclusive Mexican Rights for Arlevert® from HENNIG ARZNEIMITTEL
Sep 14, 2021
M8 Pharmaceuticals Announces License of Exclusive rights for Diacomit® (Stiripentol) from Biocodex SAS
Aug 31, 2021
M8 Pharmaceuticals Announces License of Exclusive rights MED3000 from Futura Medical for Latin America
Jul 20, 2021
Pharmanovia expands strategic collaboration with M8 Pharmaceuticals in Latin America
Jul 06, 2021
Marinomed Biotech AG Grants Exclusive Rights for Carragelose® to M8 Pharmaceuticals marketed locally as Barlo®
Partner with Us
From go-to-market strategy and registration to access and long-term market presence, M8 is a purpose-built biopharmaceutical platform that supports the entire development-commercialization continuum.
Work with Us
Our motivated team fosters a supportive and positive culture fueled by the will to bring value to the patients of Latin America.
M8 Pharmaceuticals announces strategic partnership with Janssen for selected CNS Portfolio in Mexico
Sep 29, 2020
m8 Pharmaceuticals (formerly moksha8) has entered into an exclusive promotion and distribution agreement with Janssen Cilag S.A de C.V., whereby m8 will have the rights to commercialize and promote a portfolio of selected central nervous system (CNS) brands in the Mexican market. The main goal of this strategic partnership is to create broader access to medically established brands amongst more patients, provide continued support to physicians and strengthen treatment options in Mexico.
The portfolio includes market leading established brands, indicated for the treatment of various diseases of the central nervous system. The marketing of the products by m8 commences in September of 2020.
The strong and diverse portfolio includes: CONCERTA®, HALDOL®, HALDOL® DECANOAS, REMINYL®, SIBELIUM®, RISPERDAL®, RISPERDAL CONSTA® and TOPAMAX®.
According to IQVIA, the market size of Latin America's pharmaceutical industry is projected to grow from $55 billion in 2018 to $76 billion in 2023 with a Compound Annual Growth Rate of 7%. Brazil and Mexico are the two largest countries in Latin America, accounting for 63% of the region's pharmaceutical market, and reaching a +10.3% and 7.3% respectively growth rate from 2019 to 2020 Q1. Also worthy of mention is that CNS products occupy a considerable portion of the pharmaceutical market in Latin America, accounting for $5.3 billion in 2019.
This strategic partnership reinforces m8 Pharmaceuticals position as a market leader in the CNS space in Latin America, continuing to work together with its network of global strategic partners to bring innovative treatments and greater access to patients in the region.
"We are committed to serving patients and doctors by supporting greater access to well-established market-leading brands in the Mexican market" said Joel Barlan, m8's CEO.
Joel Barlan Chief Executive Officer T: +52 (55) 4431 2933 firstname.lastname@example.org
Rafael Ferrer Vice President of Corporate Development T: +1 (305) 299 6998 email@example.com